А. Л. Бакулев

发表

Strategy “treat to target” for patients with psoriasis. Relevant issues to biological therapy persistence

A. Bakulev, А. Л. Бакулев, 2016, Vestnik dermatologii i venerologii.

A case of localized bullous scleroderma

E. Galkina, A. Bakulev, M. V. Litvinenko, 2016, Vestnik dermatologii i venerologii.

Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis

A. Kubanov, M. Kokhan, O. Olisova, 2019 .

Endothelial dysfunction and its treatment in psoriasis patients

S. Utz, A. Bakulev, A. N. Platonova, 2015, Vestnik dermatologii i venerologii.

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

A. Kubanov, A. Bakulev, V. R. Khairutdinov, 2017 .

Methotrexate: Revisited efficiency and safety of drug administration in psoriasis patients

A. Bakulev, А. Л. Бакулев, 2017, Vestnik dermatologii i venerologii.

Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis

A. Bakulev, А. Л. Бакулев, А Л Бакулев, 2019, Vestnik dermatologii i venerologii.

Results of the long-term observational noninterventional prospective study BODYGUARD in psoriasis patients

A. Bakulev, D. Petrunin, А. Л. Бакулев, 2019, Vestnik Dermatologii i Venerologii.

Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext

A. Samtsov, A. Kubanov, M. Kokhan, 2019, Vestnik dermatologii i venerologii.

Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

A. Kubanov, M. Kokhan, A. Bakulev, 2019, Vestnik dermatologii i venerologii.